Vext Science Résultats passés
Passé contrôle des critères 0/6
Vext Science has been growing earnings at an average annual rate of 1.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 10.5% per year.
Informations clés
1.2%
Taux de croissance des bénéfices
-2.7%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 7.3% |
| Taux de croissance des recettes | 10.5% |
| Rendement des fonds propres | -8.0% |
| Marge nette | -20.8% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Ventilation des recettes et des dépenses
Comment Vext Science gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 33 | -7 | 16 | 0 |
| 31 Mar 24 | 34 | -2 | 14 | 0 |
| 31 Dec 23 | 35 | 4 | 14 | 0 |
| 30 Sep 23 | 35 | 5 | 8 | 0 |
| 30 Jun 23 | 34 | 7 | 8 | 0 |
| 31 Mar 23 | 34 | 9 | 10 | 0 |
| 31 Dec 22 | 35 | 11 | 10 | 0 |
| 30 Sep 22 | 37 | 6 | 9 | 0 |
| 30 Jun 22 | 38 | 6 | 7 | 0 |
| 31 Mar 22 | 39 | 6 | 7 | 0 |
| 31 Dec 21 | 37 | 5 | 6 | 0 |
| 30 Sep 21 | 34 | 5 | 6 | 0 |
| 30 Jun 21 | 33 | 5 | 6 | 0 |
| 31 Mar 21 | 30 | 4 | 5 | 0 |
| 31 Dec 20 | 25 | 2 | 5 | 0 |
| 30 Sep 20 | 22 | 0 | 6 | 0 |
| 30 Jun 20 | 20 | 0 | 6 | 0 |
| 31 Mar 20 | 20 | 0 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 5 | 0 |
| 30 Sep 19 | 23 | 4 | 4 | 0 |
| 30 Jun 19 | 23 | 5 | 4 | 0 |
| 31 Mar 19 | 21 | 4 | 3 | 0 |
| 31 Dec 18 | 18 | 4 | 3 | 0 |
| 31 Dec 17 | 15 | 4 | 2 | 0 |
Des revenus de qualité: VV5 is currently unprofitable.
Augmentation de la marge bénéficiaire: VV5 is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: VV5 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.
Accélération de la croissance: Unable to compare VV5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: VV5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rendement des fonds propres
ROE élevé: VV5 has a negative Return on Equity (-7.97%), as it is currently unprofitable.